TY - JOUR
T1 - Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia
T2 - Temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men
AU - Cindolo, Luca
AU - Pirozzi, Luisella
AU - Fanizza, Caterina
AU - Romero, Marilena
AU - Sountoulides, Petros
AU - Roehrborn, Claus
AU - Mirone, Vincenzo
AU - Schips, Luigi
N1 - Funding Information:
Acknowledgments This study was supported by an unrestricted grant from GlaxoSmithKline Italy.
Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 2014/4
Y1 - 2014/4
N2 - Purpose: The purpose of the study is to estimate the trends in drug prescriptions and the hospitalization rates for lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) in real-life clinical practice, using information deriving from administrative databases of the Italian health care system. Methods: Prescription data on approximately 1,500,000 men over 40 were examined, and prescribed boxes of alpha-blockers (ABs) and/or 5 alpha reductase inhibitors (5ARI) were calculated for 5 consecutive years, from 2004 to 2008. Annual use prevalence and incidence rates for each drug class and for the combination therapy (CT) were calculated according to age for the entire study period. Hospitalization rates for reasons related to LUTS/BPH were also evaluated for the same time period. Results: The overall distribution of drugs for LUTS/BPH, in terms of number of boxes prescribed, increased by 43 %. This increase was accounted for by both classes of drugs although it was greater for 5ARI than for AB (+49 vs +41 %). The prevalence of CT showed a substantial increase to almost 25 % in patients aged ≥75. Hospitalization rate for BPH/LUTS-related reasons decreased during the study period (8 and 3 % per year for non-surgical and surgical reasons, respectively). Conclusions: The prevalence of the use of drugs prescribed for LUTS/BPH has steadily increased. An increase in terms of prescribed boxes was observed for both classes of drugs, even though the increase was greater for 5ARIs. The reduction in the hospitalization rates needs additional researches.
AB - Purpose: The purpose of the study is to estimate the trends in drug prescriptions and the hospitalization rates for lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) in real-life clinical practice, using information deriving from administrative databases of the Italian health care system. Methods: Prescription data on approximately 1,500,000 men over 40 were examined, and prescribed boxes of alpha-blockers (ABs) and/or 5 alpha reductase inhibitors (5ARI) were calculated for 5 consecutive years, from 2004 to 2008. Annual use prevalence and incidence rates for each drug class and for the combination therapy (CT) were calculated according to age for the entire study period. Hospitalization rates for reasons related to LUTS/BPH were also evaluated for the same time period. Results: The overall distribution of drugs for LUTS/BPH, in terms of number of boxes prescribed, increased by 43 %. This increase was accounted for by both classes of drugs although it was greater for 5ARI than for AB (+49 vs +41 %). The prevalence of CT showed a substantial increase to almost 25 % in patients aged ≥75. Hospitalization rate for BPH/LUTS-related reasons decreased during the study period (8 and 3 % per year for non-surgical and surgical reasons, respectively). Conclusions: The prevalence of the use of drugs prescribed for LUTS/BPH has steadily increased. An increase in terms of prescribed boxes was observed for both classes of drugs, even though the increase was greater for 5ARIs. The reduction in the hospitalization rates needs additional researches.
KW - 5 alpha reductase inhibitors
KW - Administrative databases
KW - Alpha-blockers
KW - Benign prostatic hyperplasia
KW - Combination therapy
UR - http://www.scopus.com/inward/record.url?scp=84897510074&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897510074&partnerID=8YFLogxK
U2 - 10.1007/s11255-013-0587-8
DO - 10.1007/s11255-013-0587-8
M3 - Article
C2 - 24136187
AN - SCOPUS:84897510074
SN - 0301-1623
VL - 46
SP - 695
EP - 701
JO - International Urology and Nephrology
JF - International Urology and Nephrology
IS - 4
ER -